对于持久性原发性免疫性血小板缺血症患者的血药:对多中心,随机的第三期试验的后期分析
Heng Mei1, Xiaofan Liu2, Yan Li3
1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Research and practice in thrombosis and haemostasis
|December 10, 2025
概括
黑特罗姆波巴格有效治疗持续性免疫血小板缺血 (ITP),显示出血小板数量的显著增加和降低出血风险. 安全性和有效性与慢性ITP患者的结果一致.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 黑特罗姆巴格已批准用于慢性免疫血小板缺血症 (ITP) (>12个月持续).
- 持续性ITP (3-12个月持续) 的有效性和安全性以前未被探索.
研究的目的:
- 评估 hetrombopag 在持续性 ITP 的疗效和安全性.
- 为了比较持续性ITP与慢性和整体ITP人群的结果.
主要方法:
- 一个III期试验 (NCT03222843) 的后期分析.
- 包括一个为期10周的随机,双盲,安慰剂控制的期间,使用异构巴格或安慰剂.
- 主要终点:响应者 (血小板数≥50 × 10^9/L) 在8周.
主要成果:
- 68.8% (2.5毫克) 和74.3% (5.0毫克) 的持久性ITP患者实现了主要终点,与安慰剂组的7.7%相比.
- 血药降低了出血风险和救援治疗需求.
- 在持久性,慢性和整体ITP群体中观察到类似的疗效和有利的安全性.
结论:
- 在持续性ITP患者中,Hetrombopag显示出良好的安全性和有效性.
- 持久性ITP的结果与慢性和整体ITP人群的结果一致.
相关概念视频
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


